Αποτελέσματα Αναζήτησης
Chordoma prognosis is generally determined by the outcome of the tumor removal surgery. Although chordomas are often slow-growing tumors, they are aggressive locally, infiltrate neighboring tissues and organs, and have several local recurrences (return of the tumor).
Between January 2003 and December 2022, 42 patients (22 males and 20 females; median age 50.8 ± 18.4 years, range 17–85 years) with clival chordoma were treated with 85 surgeries (microsurgical open and/or endoscopic endonasal procedures).
7 Ιουν 2019 · Compared with patients who received subtotal resection (n = 5, 5-year and 10-year survival = 61% and 39%, respectively), the annual survival rate of patients who received total resection (n = 55, 5-year and 10-year survival = 67%, respectively) was significantly higher.
30 Σεπ 2024 · Overall, the prognosis for patients with end-stage chordoma is typically unfavorable, and the survival rate is low. Seek advice from a healthcare professional for tailored treatment alternatives and a more precise prognosis.
22 Μαΐ 2021 · One male patient died of tumor un-related lung cancer 36 months after the initial treatment, and other patients survived throughout the observational periods. The mean overall survival was 106.7 months (range: 27–224 months). Thus, the 5-year survival rate was 94.7%.
3 Ιουλ 2023 · Because of their local invasiveness and rates of recurrence, clival chordomas are clinically malignant and have a relatively poor survival prognosis of <12 months if the patient is left untreated [5, 7]. Maximum surgical resection is the most basic requirement for treating clival chordomas [4, 8, 9, 10, 11].
9 Σεπ 2023 · A total of 42 patients underwent 85 surgeries; median follow-up was 15.8 years, overall survival rate was 49.9% at 10 years; meanwhile, progression-free survival was 26.6% at 10 years. A...
